Oncolytic Vaccinia Virus Synergizes with Irinotecan in Colorectal Cancer

Metastatic colorectal cancer (CRC) is complex clinical challenge for which there are limited treatment options. Chemotherapy with or without surgery provides moderate improvements in overall survival and quality of life; nevertheless the 5-year survival remains below 30%. Oncolytic vaccinia virus (VV) therapy has shown strong anti-tumour activity in orthotopic murine models of CRC, however transient delays in disease progression are insufficient to lead to long-term survival. Here we examined the efficacy of combining VV with oxaliplatin or SN38 (active metabolite of irinotecan) in three CRC cell lines in vitro and VV with irinotecan in an orthotopic xenograft model of metastatic CRC.

Source: Molecular Oncology - May 6, 2015 Category: Cancer & Oncology Authors: Kathryn Ottolino-Perry, Sergio A. Acuna, Fernando A. Angarita, Clara Sellers, Siham Zerhouni, Nan Tang, J.Andrea McCart Source Type: research